Corbus Pharmaceuticals Holdings Inc

Healthcare
$9.74
+0.37(3.95%) 1D
1D
1W
1M
1Y
3Y
5Y

Performance

Open PricePrev. CloseVolumeAvg. Volume
$9.29$9.3789,938112,961

Fundamentals

Market Cap$119.40M
P/B Ratio1.1
P/E Ratio-2.1
Enterprise Value$101.10M
Div. Yield0.00%
Book Value0.07
EPS(TTM)-2.27
ROENA
Understand Fundamentals

About the Company

Corbus Pharmaceuticals (CRBP) is a clinical-stage pharmaceutical business dedicated to the discovery and commercialization of new medicines for the treatment of uncommon, chronic, and severe inflammatory and fibrotic illnesses with significant unmet medical needs. Anabasum is a new synthetic oral endocannabinoid-mimetic medication that is designed to cure chronic inflammation and stop fibrotic processes without inducing immunosuppression. Anabasum is being developed to treat four potentially fatal diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus ("SLE"). The FDA of the US has given anabasum Orphan Designation and Fast Track Status for cystic fibrosis and systemic sclerosis.;
OrganisationCorbus Pharmaceuticals Holdings Inc

Company Financials

*All values are in Million $
No Graph Data To Display
Quarterly
Yearly

Similar Stocks

COMPANYMARKET PRICECLOSE PRICEMARKET CAP
Invest the way you want
Join millions of Indians who trust and love Groww